losartan has been researched along with cardiovascular agents in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bobik, A; Dilley, RJ; Oddie, CJ | 1 |
| Lie, KI; van Zwieten, PA | 1 |
| Berezin, AE; Fushteĭ, IM | 1 |
| Barr, E; Conlin, PR; DeLucca, P; Demopoulos, L; Fletcher, C; Gazdick, L; Moore, TJ; Swartz, SL | 1 |
| Drenjancevic-Peric, I; Frisbee, JC; Lombard, JH; Phillips, SA | 1 |
| Anker, SD; Banasiak, W; Cicoira, M; Clark, AL; Coats, AJ; Davos, CH; Haass, M; Pitt, B; Ponikowski, P; Poole-Wilson, PA; Senges, J; Winkler, R; Zardini, P; Zugck, C | 1 |
| Dahlöf, B; Devereux, RB | 1 |
| Davies, S; Fraser, AG; Stuart, AG; Williams, A; Wilson, DG | 1 |
| Blankesteijn, WM; Daemen, MJ; Fujimoto, A; Fujimoto, S; Hofstra, L; Isobe, S; Li, P; Lovhaug, D; Narula, J; Narula, N; Petrov, A; Pitt, B; Reutelingsperger, C; Smits, JF; van den Borne, SW; Vannan, MA; Wong, ND; Zandbergen, HR; Zannad, F | 1 |
| Bahde, R; Bandi, S; Bhargava, KK; Gupta, S; Kapoor, S; Palestro, CJ | 1 |
| Agu, RU; Feridooni, T; Mac Donald, C; Shao, D; Yeung, P | 1 |
| Arslanbekova, SM; Golukhova, EZ; Kazakov, RE; Kuznetsova, EV; Smirnov, VV; Sychev, DA | 1 |
| Vatseba, MO | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Marinšek, M; Sinkovič, A | 1 |
| Luteijn, JM; Morris, JK; Wald, NJ | 1 |
| Khanmoradi, M; Nasimi, A | 1 |
| Abd-Eldayem, AM; Abdel-Zaher, AO; El-Refaiy, AEM; Farghaly, HSM | 1 |
| Absalan, G; Ahmadi, R; Ramezani, AM | 1 |
| Bourke, JP; Bueser, T; Quinlivan, R | 1 |
| Chamorro-Pareja, N; Chirilă, RM; Marin-Acevedo, JA | 1 |
| Koiwa, H; Matsushima, S; Morisaki, H; Morisaki, T; Naya, M; Tsujinaga, S; Yokota, T | 1 |
| Ardiana, M; Harsoyo, PM; Hermawan, HO; Muhammad, AR; Sufiyah, IM; Suryawan, IGR; Zaini, BSI | 1 |
5 review(s) available for losartan and cardiovascular agents
| Article | Year |
|---|---|
[Losartan--a nonpeptide antagonist of angiotensin-II receptors in the treatment of heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cardiovascular Agents; Drug Evaluation, Preclinical; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renin-Angiotensin System | 1998 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Cardiovascular Agents; Cohort Studies; Drug Utilization; Endothelium, Vascular; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Models, Biological; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Precursors; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Stroke; Thrombosis; Treatment Outcome | 2007 |
Medical treatment of Marfan syndrome: a time for change.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Agents; Humans; Losartan; Marfan Syndrome | 2008 |
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiomyopathies; Cardiomyopathy, Dilated; Cardiovascular Agents; Child; Disease Progression; Eplerenone; Human Growth Hormone; Humans; Lisinopril; Losartan; Male; Muscular Dystrophy, Duchenne; Non-Randomized Controlled Trials as Topic; Perindopril; Placebos; Randomized Controlled Trials as Topic; Stroke Volume; Ubiquinone; Young Adult | 2018 |
Cardiac sarcoidosis: Case presentation and Review of the literature.
Topics: Cardiomyopathies; Cardiovascular Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Losartan; Methotrexate; Metoprolol; Middle Aged; Prednisone; Sarcoidosis | 2019 |
2 trial(s) available for losartan and cardiovascular agents
| Article | Year |
|---|---|
Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Agents; Circadian Rhythm; Drug Interactions; Female; Humans; Indomethacin; Losartan; Male; Middle Aged | 2000 |
Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.
Topics: Aged; Biomarkers; Cardiovascular Agents; Fibrinolysis; Heart Failure; Humans; Losartan; Middle Aged; Myocardial Infarction; Platelet Aggregation; Ramipril | 2016 |
17 other study(ies) available for losartan and cardiovascular agents
| Article | Year |
|---|---|
Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Cardiovascular Agents; Cardiovascular Physiological Phenomena; Cardiovascular System; Hindlimb; Hypertension; Imidazoles; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Time Factors | 1992 |
[Medical angiotensin II-receptor blockade in hypertension and heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Agents; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Renin; Tetrazoles | 1995 |
ELITE study raises losartan's profile in heart failure therapy debate.
Topics: Aged; Biphenyl Compounds; Cardiovascular Agents; Female; Heart Failure; Hospitalization; Humans; Imidazoles; Losartan; Male; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles | 1997 |
Chronic AT(1) receptor blockade alters mechanisms mediating responses to hypoxia in rat skeletal muscle resistance arteries.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Cardiovascular Agents; Enzyme Inhibitors; Epoprostenol; Hypoxia; In Vitro Techniques; Indomethacin; Losartan; Male; Muscle, Skeletal; NG-Nitroarginine Methyl Ester; Oxygen; Partial Pressure; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane A2, Prostaglandin H2; Thromboxane A2; Thromboxanes; Time Factors; Vascular Resistance; Vasoconstriction; Vasodilation; Vasodilator Agents | 2004 |
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
Topics: Aged; Body Mass Index; Captopril; Cardiovascular Agents; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Middle Aged; Multivariate Analysis; Oxygen Consumption; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis | 2006 |
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carbocyanines; Cardiovascular Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Fibrillar Collagens; Fibroblasts; Fibrosis; Losartan; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Oligopeptides; Predictive Value of Tests; Spironolactone; Technetium; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left; Ventricular Remodeling | 2009 |
Directly acting drugs prostacyclin or nitroglycerine and endothelin receptor blocker bosentan improve cell engraftment in rodent liver.
Topics: Animals; Bosentan; Cardiovascular Agents; Dipeptidyl Peptidase 4; Endothelin Receptor Antagonists; Epoprostenol; Hepatocytes; Lisinopril; Liver; Losartan; Nitroglycerin; Rats; Rats, Inbred F344; Sulfonamides | 2013 |
Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cardiovascular Agents; Cell Death; Cell Line; Cell Survival; Dexrazoxane; Diltiazem; Doxorubicin; Humans; Inhibitory Concentration 50; Irinotecan; Losartan; Myoblasts; Rats | 2013 |
[Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves].
Topics: Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Agents; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Monitoring; Female; Genotype; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Imidazoles; Losartan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Postoperative Period; Tetrazoles; Warfarin | 2013 |
[Endothelial dysfunction as a marker of vascular aging syndrome on the background of hypertension, coronary heart disease, gout and obesity].
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Carotid Arteries; Coronary Disease; Elasticity; Endothelium, Vascular; Female; Gout; Humans; Hypertension; Losartan; Male; Methylhydrazines; Middle Aged; Obesity; Severity of Illness Index; Tunica Intima; Tunica Media; Vascular Stiffness | 2013 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Myocardial Infarction; Preventive Health Services; Simvastatin; State Medicine; Stroke; United Kingdom | 2017 |
Functions of AT1 and AT2 angiotensin receptors in the paraventricular nucleus of the rat, correlating single-unit and cardiovascular responses.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Pressure; Cardiovascular Agents; Heart Rate; Imidazoles; Losartan; Male; Microinjections; Paraventricular Hypothalamic Nucleus; Pyridines; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 2017 |
Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Cardiovascular Agents; Ginkgo biloba; Glutathione; Hypertension; Hypertension, Renal; Interleukin-1beta; Interleukin-6; Kidney; Kidney Diseases; Losartan; Male; Malondialdehyde; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Plant Extracts; Rats; Tumor Necrosis Factor-alpha | 2018 |
Green-modified micellar liquid chromatography for isocratic isolation of some cardiovascular drugs with different polarities through experimental design approach.
Topics: Cardiovascular Agents; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Hydrophobic and Hydrophilic Interactions; Losartan; Micelles; Research Design; Software; Triamterene; United States; United States Food and Drug Administration | 2018 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; Genetic Testing; Heart Failure; Humans; Loeys-Dietz Syndrome; Losartan; Male; Middle Aged; Mutation; Pulmonary Edema; Receptor, Transforming Growth Factor-beta Type I; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2022 |
Perindopril and losartan attenuate pro-coagulation factors in human adipocytes exposed to SARS-CoV-2 spike protein.
Topics: Adipocytes; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation Factors; Cardiovascular Agents; COVID-19; Humans; Losartan; Male; Obesity; Perindopril; Plasminogen Activator Inhibitor 1; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Thromboplastin | 2023 |